Core Viewpoint - The Gross Law Firm is notifying shareholders of Fortinet, Inc. regarding a class action lawsuit related to alleged misleading statements made by the company during a specific period [1][3]. Group 1: Allegations - The complaint alleges that Fortinet misrepresented the potential profitability of its product refresh cycle, claiming it would be more lucrative than it actually was, as it involved old products that constituted a "small percentage" of the company's business [3]. - It is claimed that Fortinet did not have a clear understanding of the actual number of FortiGate firewalls eligible for upgrades, contradicting their statements to investors about the refresh gaining momentum over two years [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as November 8, 2024, to August 6, 2025, with a deadline for shareholders to register for participation set for November 21, 2025 [3][4]. - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case's progress, and there is no cost or obligation to participate [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, emphasizing the importance of responsible corporate behavior [5].

Core Viewpoint - V.F. Corporation (NYSE: VFC) is facing a class action lawsuit due to allegations of disseminating false and misleading statements regarding its turnaround plans for the Vans brand, which has resulted in significant revenue declines [1][2]. Summary by Sections Allegations - The complaint claims that VFC concealed material adverse facts about the necessary actions to return the Vans brand to growth, leading to a significant decline in revenue growth trajectory [1]. - The company's fourth quarter and full-year fiscal 2025 results revealed a decline in Vans' growth from an 8% loss in the previous quarter to a 20% loss in the fourth quarter, with expectations of continued decline [1]. Financial Impact - VFC attributed its disappointing results to "deliberately reduced revenue to eliminate unprofitable or unproductive businesses" and noted that even without these actions, Vans would have experienced a "high single digit" revenue decline [1]. - Following the announcement, VFC's stock price dropped from $14.43 per share on May 20, 2025, to $12.15 per share on May 21, 2025, marking a decline of approximately 15.8% in one day [1]. Next Steps for Shareholders - Shareholders who purchased VFC shares during the specified class period (October 30, 2023, to May 20, 2025) are encouraged to register for the class action, with a deadline to seek lead plaintiff status set for November 12, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2].

Core Viewpoint - Tronox Holdings plc (NYSE: TROX) is facing a class action lawsuit due to allegations of providing misleading statements about its financial health and sales forecasts, leading to a significant drop in stock price following disappointing financial results [1]. Summary by Sections Allegations - The complaint alleges that Tronox's management made overly positive statements while concealing material adverse facts about the company's ability to forecast demand for its products, particularly in the pigment and zircon markets [1]. - Despite ambitious long-term projections, the company's forecasting processes failed, resulting in declining sales and increased costs, which ultimately derailed revenue projections [1]. Financial Results - On July 30, 2025, Tronox reported a significant reduction in TiO2 sales for the second quarter of fiscal 2025, attributing the decline to a "softer than anticipated coatings season and heightened competitive dynamics" [1]. - Following the announcement, Tronox revised its full-year revenue guidance downward and reduced its dividend by 60% [1]. - The stock price plummeted from $5.14 per share on July 30, 2025, to $3.19 per share on July 31, 2025, marking a decline of approximately 38% in just one day [1]. Class Action Details - Shareholders who purchased shares during the class period from February 12, 2025, to July 30, 2025, are encouraged to register for the class action lawsuit [2]. - The deadline for shareholders to seek lead plaintiff status is November 3, 2025, and there is no cost or obligation to participate [2].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of KBR, Inc. regarding a class action lawsuit due to allegations of misleading statements related to the company's partnership with the U.S. Department of Defense's Transportation Command [1]. Summary by Sections Allegations - The complaint alleges that KBR's management made materially false and misleading statements about the partnership with HomeSafe, despite being aware of concerns regarding HomeSafe's ability to fulfill a global household goods contract [1]. - It is claimed that KBR's statements about its business operations and future prospects lacked a reasonable basis during the class period from May 6, 2025, to June 19, 2025 [1]. Class Action Details - Shareholders who purchased KBR shares during the specified class period are encouraged to register for the class action, with a deadline set for November 18, 2025 [2]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to false or misleading statements [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its competitive position and financial guidance during a specified period [1][2]. Summary by Relevant Sections Allegations - The complaint claims that LifeMD's management overstated the company's competitive position and was reckless in raising its 2025 guidance without properly accounting for increased customer acquisition costs in its RexMD segment and related to obesity treatment drugs [1]. Class Period - The class period for the allegations is from May 7, 2025, to August 5, 2025, during which shareholders are encouraged to register for potential lead plaintiff appointment [1][2]. Next Steps for Shareholders - Shareholders who purchased shares during the specified timeframe are advised to register for the class action, which includes enrollment in a portfolio monitoring software for status updates throughout the case lifecycle [2]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for investors who suffered losses due to misleading statements or omissions by companies [3].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) for allegedly issuing false and misleading statements regarding its drug candidate SLK during the class period from March 10, 2024, to September 29, 2025 [1]. Summary by Sections Allegations - The complaint alleges that the defendants failed to disclose that SLK and BIMZELX share the same molecular targets, specifically the inflammatory cytokines IL-17A and IL-17F [1]. - It is claimed that SLK's unique Nanobody structure would not provide a clinical benefit over the traditional monoclonal structure of BIMZELX [1]. - The assertion is made that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy [1]. - Based on these points, the defendants are said to lack a reasonable basis for their positive statements regarding SLK's superiority to monoclonal antibodies [1]. Class Action Details - Shareholders who purchased shares of MLTX during the specified class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1]. - The deadline for shareholders to register for the class action is December 15, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of KBR, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its business operations and prospects during a specific class period [1]. Group 1: Allegations and Class Period - The class period for the allegations against KBR is from May 6, 2025, to June 19, 2025 [1]. - The complaint claims that KBR's management was aware of concerns from the U.S. Department of Defense regarding HomeSafe's ability to fulfill a global household goods contract but misrepresented the situation as being without issues [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased KBR shares during the specified period are encouraged to register for the class action by November 18, 2025, to potentially become lead plaintiffs [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to deceitful practices and misleading statements by companies [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Semler Scientific, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose a material investigation by the U.S. Department of Justice [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from March 10, 2021, to April 15, 2025 [2]. - Allegations include that Semler Scientific did not disclose a material investigation by the U.S. Department of Justice related to violations of the False Claims Act [2]. - The deadline for shareholders to register for the class action is October 28, 2025 [3]. Group 2: Next Steps for Shareholders - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

https://securitiesclasslaw.com/securities/fortinet-inc-loss-submission-form/?id=173408&from=4 CLASS PERIOD: November 8, 2024 to August 6, 2025 Accessibility StatementSkip Navigation NEW YORK, Oct. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fortinet, Inc. (NASDAQ: FTNT). Shareholders who purchased shares of FTNT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not r ...

Core Points - The Gross Law Firm has issued a notice to shareholders of Cytokinetics, Incorporated regarding potential lead plaintiff appointments in a class action lawsuit related to misleading statements about the New Drug Application (NDA) for aficamten [1][2] - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, during which shareholders are encouraged to register for participation [2] - Allegations include that Cytokinetics misrepresented the timeline for FDA approval and failed to disclose risks associated with not submitting a Risk Evaluation and Mitigation Strategy (REMS), leading to inflated stock prices and subsequent losses for investors when the truth was revealed [1] Company Specifics - Cytokinetics is facing legal scrutiny for allegedly making materially false and misleading statements regarding its NDA submission process for aficamten, which is critical for its market position [1] - The company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, which could have significant implications for its regulatory approval process [1] Legal Context - The Gross Law Firm is recognized for its commitment to protecting investor rights and seeks recovery for those who suffered losses due to misleading corporate practices [3] - Shareholders are advised to register by November 17, 2025, to be included in the monitoring of the case's progress [2]